Advisor Group Holdings, Inc. Homology Medicines, Inc. Transaction History

Advisor Group Holdings, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$0.83 - $1.12 $1,202 - $1,622	-1,449 Reduced 83.81%	280 $0
Q1 2023 May 12, 2023	BUY	$0.91 - $1.69 $677 - $1,257	744 Added 75.53%	1,729 $1,000
Q4 2022 Feb 10, 2023	BUY	$1.09 - $2.04 $54 - $102	50 Added 5.35%	985 $1,000
Q2 2022 Aug 10, 2022	SELL	$1.39 - $3.12 $5,004 - $11,232	-3,600 Reduced 79.38%	935 $2,000
Q1 2022 May 04, 2022	SELL	$2.6 - $4.17 $48,659 - $78,041	-18,715 Reduced 80.49%	4,535 $14,000
Q3 2021 Nov 05, 2021	SELL	$6.01 - $8.71 $3,005 - $4,355	-500 Reduced 2.11%	23,250 $182,000
Q2 2021 Aug 02, 2021	BUY	$6.02 - $9.64 $16,253 - $26,028	2,700 Added 12.83%	23,750 $173,000
Q1 2021 May 13, 2021	SELL	$9.17 - $14.8 $183 - $296	-20 Reduced 0.09%	21,050 $198,000
Q4 2020 Feb 10, 2021	SELL	$8.92 - $13.29 $1,784 - $2,658	-200 Reduced 0.94%	21,070 $238,000
Q3 2020 Nov 12, 2020	BUY	$9.94 - $16.59 $8,946 - $14,931	900 Added 4.42%	21,270 $228,000
Q2 2020 Aug 14, 2020	SELL	$12.07 - $19.34 $1,774 - $2,842	-147 Reduced 0.72%	20,370 $309,000
Q1 2020 May 18, 2020	BUY	$12.5 - $22.04 $256,462 - $452,194	20,517 New	20,517 $319,000

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.